A71 Stock Overview
A biopharmaceutical company, focuses on developing TransCon-based therapies for unmet medical needs in Denmark, rest of Europe, North America, and internationally. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 5/6 |
| Past Performance | 0/6 |
| Financial Health | 1/6 |
| Dividends | 0/6 |
Community vs My Fair Value
Create NarrativeSelect a narrative for quick price alerts from the community, or create your own.
My Notes
Capture your thoughts, links and company narrative
Ascendis Pharma A/S Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$138.00 |
| 52 Week High | US$147.00 |
| 52 Week Low | US$99.00 |
| Beta | 0.64 |
| 1 Month Change | 7.81% |
| 3 Month Change | 16.95% |
| 1 Year Change | -4.17% |
| 3 Year Change | 41.54% |
| 5 Year Change | 14.05% |
| Change since IPO | 725.21% |
Recent News & Updates
Recent updates
Shareholder Returns
| A71 | DE Biotechs | DE Market | |
|---|---|---|---|
| 7D | 20.0% | -11.3% | 3.0% |
| 1Y | -4.2% | -15.0% | 19.3% |
Return vs Industry: A71 exceeded the German Biotechs industry which returned -16.5% over the past year.
Return vs Market: A71 underperformed the German Market which returned 18.5% over the past year.
Price Volatility
| A71 volatility | |
|---|---|
| A71 Average Weekly Movement | 7.0% |
| Biotechs Industry Average Movement | 8.4% |
| Market Average Movement | 4.8% |
| 10% most volatile stocks in DE Market | 11.4% |
| 10% least volatile stocks in DE Market | 2.5% |
Stable Share Price: A71 has not had significant price volatility in the past 3 months compared to the German market.
Volatility Over Time: A71's weekly volatility (7%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2006 | 1,017 | Jan Mikkelsen | ascendispharma.com |
Ascendis Pharma A/S, a biopharmaceutical company, focuses on developing TransCon-based therapies for unmet medical needs in Denmark, rest of Europe, North America, and internationally. The company offers SKYTROFA for treating pediatric patients with growth hormone deficiency; and YORVIPATH, a once-daily subcutaneous injection for the treatment of adults with chronic hypoparathyroidism. It also develops a pipeline of three independent endocrinology rare disease product candidates in clinical development, as well as focuses on advancing oncology therapeutic candidates.
Ascendis Pharma A/S Fundamentals Summary
| A71 fundamental statistics | |
|---|---|
| Market cap | €8.25b |
| Earnings (TTM) | -€378.08m |
| Revenue (TTM) | €363.64m |
24.6x
P/S Ratio-23.7x
P/E RatioIs A71 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| A71 income statement (TTM) | |
|---|---|
| Revenue | €363.64m |
| Cost of Revenue | €44.26m |
| Gross Profit | €319.38m |
| Other Expenses | €697.47m |
| Earnings | -€378.08m |
Last Reported Earnings
Dec 31, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -6.32 |
| Gross Margin | 87.83% |
| Net Profit Margin | -103.97% |
| Debt/Equity Ratio | -722.4% |
How did A71 perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/02/18 20:19 |
| End of Day Share Price | 2025/02/18 00:00 |
| Earnings | 2024/12/31 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Ascendis Pharma A/S is covered by 22 analysts. 14 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Tazeen Ahmad | BofA Global Research |
| Michelle Gilson | Canaccord Genuity |
| Alethia Young | Cantor Fitzgerald & Co. |